Characteristics | Denosumab treatment adherence at 24Â months | p-value c | |
---|---|---|---|
Adherent group (n = 17) b | Non-adherent group (n = 11) b | ||
Age (years), median (IQR) | 39.0 (36.0–43.3) | 39.0 (34.0–45.0) | 0.962 |
Gender, male, n (%) | 15 (88.2) | 10 (90.9) | 1.000 |
BMI (kg/m2), median (IQR) | 21.4 (19.2–24.7) | 19.0 (18.6–20.7) | 0.145 |
Current smoking, n (%) | 6 (35.3) | 6 (54.5) | 0.441 |
Prior AIDS diagnosis, n (%) | 4 (23.5) | 6 (54.5) | 0.125 |
Time since diagnosis HIV (years), median (IQR) | 5 (1–10) | 1 (0–4) | 0.007 |
CD4 cell count (cells/µL), median (IQR) | 534 (373–805) | 355 (149–827) | 0.158 |
Time on antiretroviral therapy (years), median (IQR) | 4 (2–10) | 1 (1–3) | 0.005 |
Denosumab treatment initiated before the COVID-19 pandemic, n (%) | 16 (94.1) | 6 (54.5) | 0.022 |